Evidence map›Paper›PMID 41165438›Full record

ArticleMolecular genetics & genomic medicine2025

Mexican Patients With Suspected 22q11.2 Deletion Syndrome: Clinical Characterization and Molecular Findings by Fluorescence In Situ Hybridization and Multiplex Ligation-Dependent Probe Amplification.

Thania Alejandra Aguayo-Orozco, Horacio Rivera, Luis E Figuera, Eduardo Esparza-García, Francisco Javier Perea-Díaz, Ana Rebeca Jaloma-Cruz, Lourdes Del Carmen Rizo-de la Torre, Ma Guadalupe Domínguez-Quezada

Abstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Thania Alejandra Aguayo-OrozcoDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.ORCID https://orcid.org/0000-0002-2645-4161
Horacio RiveraDoctorado en Genética Humana, Centro Universitario de Ciencias de la Salud - Universidad de Guadalajara, Guadalajara, Jalisco, México.
Luis E FigueraDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.ORCID https://orcid.org/0000-0002-6096-4579
Eduardo Esparza-GarcíaUnidad Médica de Alta Especialidad, Hospital de Pediatría - Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Francisco Javier Perea-DíazDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Ana Rebeca Jaloma-CruzDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Lourdes Del Carmen Rizo-de la TorreDivisión de Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Ma Guadalupe Domínguez-QuezadaDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.

Funding

CONACYT 826522Instituto Mexicano del Seguro Social FIS/IMSS/PROT/G18/1817
6 · The paper itself

Abstract

backgroundThe 22q11.2 deletion syndrome (22q11.2DS) is mostly caused by deletions of 3 and 1.5 Mb, referred to as typical deletions, although atypical deletions have also been reported. The commonest features are congenital heart disease, immunodeficiency, facial dysmorphism, and developmental delay. However, phenotypic variability is remarkable, and the underlying mechanisms remain poorly understood.

objectiveTo determine copy number variations (CNVs) in the 22q11.2 region and their association with clinical manifestations in Mexican patients with suspected 22q11.2DS.

methodsFluorescence in situ Hybridization (FISH) and Multiplex Ligation-dependent Probe Amplification (MLPA) assays were performed in 80 patients with suspected 22q11.2DS. Clinical characterization was carried out according to the criteria used by the 22q11.2 Consortium.

resultsFISH detected deletions in 51%, while MLPA detected CNVs in 54%. Typical deletions were observed in 86% of patients, whereas atypical deletions were found in 14%, including CNVs involving single genes (TBX1, TOP3B, and PRODH). Three families were identified with the 3 Mb deletion and exhibited a heterogeneous phenotype that cannot be explained by the microdeletion alone.

conclusion22q11.2DS is a complex disorder for which MLPA is recommended to detect atypical deletions in FISH-negative patients, and to define deletion size, breakpoints, and genes in FISH-positive ones.

Indexed as

DiGeorge SyndromeAdolescentAdultChildChild, PreschoolDNA Copy Number VariationsFemaleHumansInfantIn Situ Hybridization, FluorescenceMaleMexicoMultiplex Polymerase Chain ReactionPhenotypeT-Box Domain ProteinsT-Box Domain ProteinsTBX1 protein, human22q11.2 deletion syndromefluorescence in situ hybridizationMexican patientsmultiplex ligation‐dependent probe amplificationphenotypic variabilityTBX1 gene

Identifiers

PMID41165438
PMCPMC12573781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.